Our findings now suggest that aberrant ROCK2 activation, by blocking the proteasome-dependent degradation of MYC, can promote increased MYC protein levels in ABC-DLBCL potentially leading to its over-expression. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.